JPMorgan Funds -
Thematics - Genetic Therapies
Class: JPM Thematics - Genetic Therapies A (acc) - USD

Fund overview

ISIN: LU2050612402
Valor: 500772717
Bloomberg: JGTAUA LX

Investment objective: To achieve a return by investing in companies with exposure to the theme of genetic therapies, globally.

Investment approach:
- Uses the ThemeBot which, through natural language processing, determines textual relevance and revenue attribution to identify companies with the highest exposure to the theme.
- Considers insights from a team of specialist sector analysts who review the ThemeBot’s results to assess their appropriateness for the portfolio.
- Determines the position sizes of the securities identified as having the highest exposure to the theme by taking into consideration not only textual relevance and revenue attribution but also their quality, liquidity and market capitalisation.

Portfolio manager(s):
- Yazann Romahi
- Berkan Sesen
- Aijaz Hussain
- Investment specialist(s):
  - Sherene Ban
  - Katherine Magee

Fund reference:
- Currency: USD
- Share class: acc

Fund ratings

As at 30 April 2020
Morningstar Category™: Sector Equity Biotechnology

Performance

GROWTH OF USD 100,000 (in thousands) Calendar years

Due to local regulation, we are unable to show performance for the first 12 months.

CALENDAR YEAR PERFORMANCE (%)

Due to local regulation, we are unable to show performance for the first 12 months.

RETURN (%) CUMULATIVE 3 years 5 years ANNUALISED 1 year Launch

1
2
3
4
5
6
7

Lower risk/ potential reward Not risk-free Higher risk/ potential reward

PERFORMANCE DISCLOSURES

Past performance is not a guide to current and future performance. The value of your investments and any income from them may fall as well as rise and you may not get back the full amount you invested.

Source: J.P. Morgan Asset Management. Share class performance is shown based on the NAV (net asset value) of the share class with income (gross) reinvested including actual ongoing charges excluding any entry and exit fees. The return of your investment may change as a result of currency fluctuations if your investment is made in a currency other than that used in the past performance calculation. Indices do not include fees or operating expenses and you cannot invest in them. The benchmark is for comparative purposes only unless specifically referenced in the Sub-Funds' Investment Objective and Policy.

See the material risks, general disclosures and definitions on pages 2 & 3.
Holdings

**TOP 10**

<table>
<thead>
<tr>
<th>Sector</th>
<th>% of assets</th>
</tr>
</thead>
<tbody>
<tr>
<td>uniQure</td>
<td>2.6</td>
</tr>
<tr>
<td>Iovance Biotherapeutics</td>
<td>2.3</td>
</tr>
<tr>
<td>Regeneron Pharmaceuticals</td>
<td>2.3</td>
</tr>
<tr>
<td>Alnylam Pharmaceuticals</td>
<td>2.1</td>
</tr>
<tr>
<td>Roche</td>
<td>2.0</td>
</tr>
<tr>
<td>Sarepta Therapeutics</td>
<td>2.0</td>
</tr>
<tr>
<td>Repligen</td>
<td>2.0</td>
</tr>
<tr>
<td>CRISPR Therapeutics</td>
<td>2.0</td>
</tr>
<tr>
<td>Gilead Sciences</td>
<td>2.0</td>
</tr>
<tr>
<td>Vertex Pharmaceuticals</td>
<td>1.9</td>
</tr>
</tbody>
</table>

**REGIONS (%)**

<table>
<thead>
<tr>
<th>Region</th>
<th>% of assets</th>
</tr>
</thead>
<tbody>
<tr>
<td>North America</td>
<td>72.8</td>
</tr>
<tr>
<td>Europe &amp; Middle East ex UK</td>
<td>9.7</td>
</tr>
<tr>
<td>Japan</td>
<td>7.9</td>
</tr>
<tr>
<td>Emerging Markets</td>
<td>6.7</td>
</tr>
<tr>
<td>Pacific ex-Japan</td>
<td>2.6</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>0.1</td>
</tr>
<tr>
<td>Cash</td>
<td>0.2</td>
</tr>
</tbody>
</table>

**Compared to benchmark**

+12.2
-3.3
+0.7
-5.2
-0.6
-4.0
+0.2

Key risks

The Sub-Fund is subject to Investment risks and Other associated risks from the techniques and securities it uses to seek to achieve its objective. The table on the right explains how these risks relate to each other and the Outcomes to the Shareholder that could affect an investment in the Sub-Fund.

Investors should also read Risk Descriptions in the Prospectus for a full description of each risk.

Investment risks **Risks from the Sub-Fund’s techniques and securities**

**Techniques**

<table>
<thead>
<tr>
<th>Concentration</th>
<th>Hedging</th>
<th>Thematic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Securities</td>
<td>Emerging markets</td>
<td>Equities</td>
</tr>
<tr>
<td>Smaller companies</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Other associated risks **Further risks the Sub-Fund is exposed to from its use of the techniques and securities above**

<table>
<thead>
<tr>
<th>Currency</th>
<th>Liquidity</th>
<th>Market</th>
</tr>
</thead>
</table>

Outcomes to the Shareholder **Potential impact of the risks above**

<table>
<thead>
<tr>
<th>Loss</th>
<th>Volatility</th>
<th>Failure to meet the Sub-Fund’s objective</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shareholders could lose some or all of their money.</td>
<td>Shares of the Sub-Fund will fluctuate in value.</td>
<td></td>
</tr>
</tbody>
</table>

GENERAL DISCLOSURES

This is a marketing communication.

Before investing, obtain and review the current prospectus, Key Investor Information Document (KIID) and any applicable local offering document. These documents, as well as the annual and semi-annual reports and the articles of incorporation, are available free from your financial adviser, your J.P. Morgan Asset Management regional contact, the document issuer (see below) or at www.jpmam.ch.

JPMorgan Asset Management (Switzerland) LLC herewith informs investors that with respect to its distribution activities in and from Switzerland it receives commissions pursuant to Art. 34 para. 2bis of the Swiss Collective Investment Schemes Ordinance dated 22 November 2006. These commissions are paid out of the management fee as defined in the fund documentation. Further information regarding these commissions, including their calculation method, may be obtained upon written request from JPMorgan Asset Management (Switzerland) LLC, Dreikönigstrasse 37, 8002 Zurich.

This material should not be considered as advice or an investment recommendation. Fund holdings and performance are likely to have changed since the report date. No provider of information presented here, including index and ratings information, is liable for damages or losses of any type arising from use of their information. No warranty of accuracy is given and no liability in respect of any error or omission is accepted.

To the extent permitted by applicable law, we may record telephone calls and monitor electronic communications to comply with our legal and regulatory obligations and internal policies. Personal data will be collected, stored and processed by J.P. Morgan Asset Management in accordance with our EMEA Privacy Policy www.jpmorgan.com/emea-privacy-policy

For additional information on the sub-fund’s target market please refer to the Prospectus.

INFORMATION SOURCES

Fund information, including performance calculations and other data, is provided by J.P. Morgan Asset Management (the marketing name for the asset management businesses of JPMorgan Chase & Co. and its affiliates worldwide).

**All data is as at the document date unless indicated otherwise.**

© 2020 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. The benchmark is for comparative purposes only unless specifically referenced in the Sub-Fund’s Investment Objective and Policy.

Benchmark Source: MSCI. Neither MSCI nor any other party involved in or related to compiling, computing or creating the MSCI data makes any express or implied warranties or representations with respect to such data (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of such data. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved, in or related to compiling, computing, or creating the data have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages. No further distribution or dissemination of the MSCI data is permitted without MSCI’s express written consent.

ISSUER